Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A new addition to the PD-1 checkpoint inhibitors for non-small cell lung cancer-the anti-PDL1 antibody-MEDI4736.

Literature DB >> 25806336

A new addition to the PD-1 checkpoint inhibitors for non-small cell lung cancer-the anti-PDL1 antibody-MEDI4736.

Sylvia M Lee¹, Laura Q Chow¹.

Abstract

Entities: Disease Gene

Year: 2014 PMID： 25806336 PMCID： PMC4367681 DOI： 10.3978/j.issn.2218-6751.2014.11.10

Source DB: PubMed Journal: Transl Lung Cancer Res ISSN： 2218-6751

× No keyword cloud information.

8 in total

Review 1. Cancer immunotherapy comes of age.

Authors: Ira Mellman; George Coukos; Glenn Dranoff
Journal: Nature Date: 2011-12-21 Impact factor: 49.962

2. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors: Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal: N Engl J Med Date: 2012-06-02 Impact factor: 91.245

3. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

Authors: Julie R Brahmer; Scott S Tykodi; Laura Q M Chow; Wen-Jen Hwu; Suzanne L Topalian; Patrick Hwu; Charles G Drake; Luis H Camacho; John Kauh; Kunle Odunsi; Henry C Pitot; Omid Hamid; Shailender Bhatia; Renato Martins; Keith Eaton; Shuming Chen; Theresa M Salay; Suresh Alaparthy; Joseph F Grosso; Alan J Korman; Susan M Parker; Shruti Agrawal; Stacie M Goldberg; Drew M Pardoll; Ashok Gupta; Jon M Wigginton
Journal: N Engl J Med Date: 2012-06-02 Impact factor: 91.245

4. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

Authors: Caroline Robert; Antoni Ribas; Jedd D Wolchok; F Stephen Hodi; Omid Hamid; Richard Kefford; Jeffrey S Weber; Anthony M Joshua; Wen-Jen Hwu; Tara C Gangadhar; Amita Patnaik; Roxana Dronca; Hassane Zarour; Richard W Joseph; Peter Boasberg; Bartosz Chmielowski; Christine Mateus; Michael A Postow; Kevin Gergich; Jeroen Elassaiss-Schaap; Xiaoyun Nicole Li; Robert Iannone; Scot W Ebbinghaus; S Peter Kang; Adil Daud
Journal: Lancet Date: 2014-07-15 Impact factor: 79.321

5. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

Authors: Suzanne L Topalian; Mario Sznol; David F McDermott; Harriet M Kluger; Richard D Carvajal; William H Sharfman; Julie R Brahmer; Donald P Lawrence; Michael B Atkins; John D Powderly; Philip D Leming; Evan J Lipson; Igor Puzanov; David C Smith; Janis M Taube; Jon M Wigginton; Georgia D Kollia; Ashok Gupta; Drew M Pardoll; Jeffrey A Sosman; F Stephen Hodi
Journal: J Clin Oncol Date: 2014-03-03 Impact factor: 44.544

6. Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.

Authors: Daniel S Chen; Bryan A Irving; F Stephen Hodi
Journal: Clin Cancer Res Date: 2012-10-19 Impact factor: 12.531

Review 7. Programmed death ligand 2 in cancer-induced immune suppression.

Authors: Esdy N Rozali; Stanleyson V Hato; Bruce W Robinson; Richard A Lake; W Joost Lesterhuis
Journal: Clin Dev Immunol Date: 2012-04-29

8. Immunotherapy earns its spot in the ranks of cancer therapy.

Authors: Drew Pardoll; Charles Drake
Journal: J Exp Med Date: 2012-02-13 Impact factor: 14.307

8 in total

12 in total

Review 1. The changing landscape of phase I trials in oncology.

Authors: Kit Man Wong; Anna Capasso; S Gail Eckhardt
Journal: Nat Rev Clin Oncol Date: 2015-11-10 Impact factor: 66.675

Review 2. Trial Watch: Immunotherapy plus radiation therapy for oncological indications.

Authors: Erika Vacchelli; Norma Bloy; Fernando Aranda; Aitziber Buqué; Isabelle Cremer; Sandra Demaria; Alexander Eggermont; Silvia Chiara Formenti; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal: Oncoimmunology Date: 2016-07-25 Impact factor: 8.110

Review 3. Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential.

Authors: Gregory T Wurz; Chiao-Jung Kao; Michael W DeGregorio
Journal: Ther Adv Med Oncol Date: 2016-01 Impact factor: 8.168

Review 4. Lung cancer: Biology and treatment options.

Authors: Hassan Lemjabbar-Alaoui; Omer Ui Hassan; Yi-Wei Yang; Petra Buchanan
Journal: Biochim Biophys Acta Date: 2015-08-19

5. Predictive and prognostic significance of CD8⁺ tumor-infiltrating lymphocytes in patients with luminal B/HER 2 negative breast cancer treated with neoadjuvant chemotherapy.

Authors: Khalid Al-Saleh; Nashwa Abd El-Aziz; Arwa Ali; Waleed Abozeed; Ahmed Abd El-Warith; Ahmed Ibraheem; Jawaher Ansari; Ammar Al-Rikabi; Sufia Husain; Jean-Marc Nabholtz
Journal: Oncol Lett Date: 2017-05-10 Impact factor: 2.967

Review 6. Integration of tobacco cessation services into multidisciplinary lung cancer care: rationale, state of the art, and future directions.

Authors: Graham W Warren; Kenneth D Ward
Journal: Transl Lung Cancer Res Date: 2015-08

Review 10. The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients.

Authors: Xinbing Sui; Junhong Ma; Weidong Han; Xian Wang; Yong Fang; Da Li; Hongming Pan; Li Zhang
Journal: Oncotarget Date: 2015-08-14